I have a quick question for Dr. Lucas.
Health Canada's approval of monoclonal antibody combinations, specifically the Eli Lilly bamlanivimab-etesevimab combination and Regeneron's.... Those applications for approval have been there since February, and growing evidence suggests that the combinations are quite effective in preventing the progression to severe disease. Obviously our ICUs are overflowing. The NIH is recommending, because of the American variants, that we use these in Canada—at least in Ontario. Bamlanivimab alone, it seems, would cover 90% to 92% of the variants in Ontario.
When can we expect to hear something from Health Canada on these other monoclonal antibodies? Can this be expedited given the situation, particularly in Ontario?